CD4 and Miyoshi myopathy: M1 TAM showed an improved antigen-presenting capacity and the ability to enhance a cytotoxic CD4+ T cell response, further supporting the hypothesis that M2 TAM, conversely, play a relevant role in the decreased T cell activation and resulting immunosuppression reported in MM, ultimately leading to disease progression [110].